Contrast developer Guerbet reported a drop in revenues for 2020 due to the ongoing COVID-19 pandemic.
For the full fiscal year (end-December 31), the firm posted revenue of 712.3 million euros ($862.9 million U.S.) at current exchange rates, down 12.8% compared with revenue of 816.9 million euros ($989.6 million) in 2019. However, at constant exchange rates, Guerbet's revenue was down 10% at 735.4 million euros ($890.8 million).
For diagnostic imaging in particular, revenue totaled 637.2 million euros ($771.9 million U.S.), down 11.4% at constant exchange rates, compared with 719.4 million euros ($871.5 million U.S.) in 2019.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
